Oncolytic Virus Solid Tumors
- TAK-605 (TBio-6517; RIVAL-01) is a candidate from Turnstone Biologic’s oncolytic vaccinia virus platform, engineered for enhanced immune-stimulation and tumor cell selectivity, potent oncolysis and large transgene carrying capacity
- Turnstone and Takeda will co-develop and co-commercialize TAK-605 (TBio-6517; RIVAL-01) under a 50:50 global profit share
TAK-605 (TBio-6517; RIVAL-01) consists of the vaccinia virus backbone encoding transgenes for FIt3 ligand, anti-CTLA-4 antibody and IL-12 p35 cytokine
A Phase 1/2a, Multicenter, Open-label Trial of TBio-6517, an Oncolytic Vaccinia Virus, Administered by Intratumoral Injection, Alone and in Combination With Pembrolizumab, in Patients With Advanced Solid Tumors
1. Turnstone Biologics Press Release.
2. Takeda, Data on file.
*In collaboration with Turnstone Biologics.
Takeda Live Chat
On exiting, all chat history will be cleared